利妥昔单抗介导的肺损伤的临床特点、处理经验及危险因素

Risk factors and management of rituximab-induced lung injuries

目的:总结利妥昔单抗介导肺损伤的临床特点及处理经验,探讨其可能的危险因素。方法:回顾性分析163例应用利妥昔单抗治疗的患者的临床资料。结果:利妥昔单抗介导的肺损伤发生率为10.4%,年龄是肺损伤发生的高危因素;肺损伤多发生于应用利妥昔单抗3个疗程后,临床常表现为发热、呼吸困难、低氧血症,影像学常表现为间质性肺病,大部分患者对激素治疗有效。结论:利妥昔单抗介导的肺损伤是利妥昔单抗的常见不良反应,及时诊断治疗非常关键。

Objective：To study the clinical course,characteristics and risk factors of rituximab-induced lung injuries.Method：The clinical data of 163 patients treated with rituximab were retrospectively analyzed.Result：Rituximab-induced lung injuries occurred in 10.4% patients;Age was a risk factor for lung injury.Most of lung injuries occurred after 3 courses of rituximab treatment with clinical manifestations as fever,dyspnea,hypoxemia and imaging manifested as interstitial lung disease;Steroid therapy was effective in most patients.Conclusion：Rituximabinduced lung injury is one of the common side effects of rituximab,which needs timely diagnosis and treatment.